Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 486

1.

Re: Identification and Characterization of Circulating Tumor Cells in Men Who Have Undergone Prostatectomy of Clinically Localized, High Risk Prostate Cancer.

Dong L, Pienta KJ.

Eur Urol. 2019 Aug 30. pii: S0302-2838(19)30678-5. doi: 10.1016/j.eururo.2019.08.028. [Epub ahead of print] No abstract available.

PMID:
31477346
2.

Prospective Comparison of PET Imaging with PSMA-targeted 18F-DCFPyL versus Na18F for Bone Lesion Detection in Patients with Metastatic Prostate Cancer.

Rowe SP, Li X, Trock BJ, Werner RA, Frey SM, DiGianvittorio M, Bleiler K, Reyes DK, Abdallah R, Pienta KJ, Gorin MA, Pomper MG.

J Nucl Med. 2019 Aug 26. pii: jnumed.119.227793. doi: 10.2967/jnumed.119.227793. [Epub ahead of print]

PMID:
31451492
3.

Detection and isolation of disseminated tumor cells in bone marrow of patients with clinically localized prostate cancer.

Cackowski FC, Wang Y, Decker JT, Sifuentes C, Weindorf S, Jung Y, Wang Y, Decker AM, Yumoto K, Szerlip N, Buttitta L, Pienta KJ, Morgan TM, Taichman RS.

Prostate. 2019 Oct;79(14):1715-1727. doi: 10.1002/pros.23896. Epub 2019 Aug 26.

PMID:
31449673
4.

Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins Experience.

Deek MP, Yu C, Phillips R, Song DY, Deville C, Greco S, DeWeese TL, Antonarakis ES, Markowski M, Paller C, Denmeade S, Carducci M, Walsh PC, Pienta KJ, Eisenberger M, Tran PT.

Int J Radiat Oncol Biol Phys. 2019 Aug 13. pii: S0360-3016(19)33641-7. doi: 10.1016/j.ijrobp.2019.08.008. [Epub ahead of print]

5.

Can the interplay between androgen signaling and PSMA expression be leveraged for theranostic applications?

Batra JS, Pienta KJ, Pomper MG, Gorin MA, Rowe SP.

Transl Androl Urol. 2019 Jul;8(Suppl 3):S263-S264. doi: 10.21037/tau.2019.03.13. No abstract available.

6.

Polyploid giant cancer cells: Unrecognized actuators of tumorigenesis, metastasis, and resistance.

Amend SR, Torga G, Lin KC, Kostecka LG, de Marzo A, Austin RH, Pienta KJ.

Prostate. 2019 Sep;79(13):1489-1497. doi: 10.1002/pros.23877. Epub 2019 Aug 2. Review.

PMID:
31376205
7.

Mannose Receptor-positive Macrophage Infiltration Correlates with Prostate Cancer Onset and Metastatic Castration-resistant Disease.

Zarif JC, Baena-Del Valle JA, Hicks JL, Heaphy CM, Vidal I, Luo J, Lotan TL, Hooper JE, Isaacs WB, Pienta KJ, De Marzo AM.

Eur Urol Oncol. 2019 Jul;2(4):429-436. doi: 10.1016/j.euo.2018.09.014. Epub 2018 Oct 19.

PMID:
31277779
8.

Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer: An Update on Important Pitfalls.

Sheikhbahaei S, Werner RA, Solnes LB, Pienta KJ, Pomper MG, Gorin MA, Rowe SP.

Semin Nucl Med. 2019 Jul;49(4):255-270. doi: 10.1053/j.semnuclmed.2019.02.006. Epub 2019 Mar 4. Review.

PMID:
31227049
9.

Prospective Evaluation of PSMA-Targeted 18F-DCFPyL PET/CT in Men with Biochemical Failure after Radical Prostatectomy for Prostate Cancer.

Rowe SP, Campbell SP, Mana-Ay M, Szabo Z, Allaf ME, Pienta KJ, Pomper MG, Ross AE, Gorin MA.

J Nucl Med. 2019 Jun 14. pii: jnumed.119.226514. doi: 10.2967/jnumed.119.226514. [Epub ahead of print]

PMID:
31201249
10.

Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptake.

Werner RA, Bundschuh RA, Bundschuh L, Lapa C, Yin Y, Javadi MS, Buck AK, Higuchi T, Pienta KJ, Pomper MG, Lodge MA, Gorin MA, Rowe SP.

Mol Imaging Biol. 2019 May 28. doi: 10.1007/s11307-019-01375-w. [Epub ahead of print]

PMID:
31140110
11.

Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Intrapatient and Interpatient Variability of Normal Organ Uptake.

Sahakyan K, Li X, Lodge MA, Werner RA, Bundschuh RA, Bundschuh L, Kulkarni HR, Schuchardt C, Baum RP, Pienta KJ, Pomper MG, Ross AE, Gorin MA, Rowe SP.

Mol Imaging Biol. 2019 May 21. doi: 10.1007/s11307-019-01376-9. [Epub ahead of print]

PMID:
31115751
12.

Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment.

Myers KV, Amend SR, Pienta KJ.

Mol Cancer. 2019 May 14;18(1):94. doi: 10.1186/s12943-019-1022-2. Review.

13.

Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone.

McKay RR, Ye H, Xie W, Lis R, Calagua C, Zhang Z, Trinh QD, Chang SL, Harshman LC, Ross AE, Pienta KJ, Lin DW, Ellis WJ, Montgomery B, Chang P, Wagner AA, Bubley GJ, Kibel AS, Taplin ME.

J Clin Oncol. 2019 Apr 10;37(11):923-931. doi: 10.1200/JCO.18.01777. Epub 2019 Feb 27.

PMID:
30811282
14.

The role of heterogeneous environment and docetaxel gradient in the emergence of polyploid, mesenchymal and resistant prostate cancer cells.

Lin KC, Torga G, Sun Y, Axelrod R, Pienta KJ, Sturm JC, Austin RH.

Clin Exp Metastasis. 2019 Apr;36(2):97-108. doi: 10.1007/s10585-019-09958-1. Epub 2019 Feb 27.

PMID:
30810874
15.

Imaging and Characterization of Macrophage Distribution in Mouse Models of Human Prostate Cancer.

Copeland BT, Shallal H, Shen C, Pienta KJ, Foss CA, Pomper MG.

Mol Imaging Biol. 2019 Feb 25. doi: 10.1007/s11307-019-01318-5. [Epub ahead of print]

PMID:
30805886
16.

Novel Structured Reporting Systems for Theranostic Radiotracers.

Werner RA, Bundschuh RA, Bundschuh L, Fanti S, Javadi MS, Higuchi T, Weich A, Pienta KJ, Buck AK, Pomper MG, Gorin MA, Herrmann K, Lapa C, Rowe SP.

J Nucl Med. 2019 May;60(5):577-584. doi: 10.2967/jnumed.118.223537. Epub 2019 Feb 22.

PMID:
30796171
17.

Hereditary Spherocytosis Presenting as Diffuse Bone Marrow Activation and Splenomegaly on PSMA-Targeted 18F-DCFPyL PET/CT.

Gomez E, Tran PT, Pienta KJ, Pomper MG, Gorin MA, Rowe SP.

Clin Nucl Med. 2019 Apr;44(4):e313-e314. doi: 10.1097/RLU.0000000000002489.

PMID:
30789396
18.

Metastatic prostate cancer remains incurable, why?

Dong L, Zieren RC, Xue W, de Reijke TM, Pienta KJ.

Asian J Urol. 2019 Jan;6(1):26-41. doi: 10.1016/j.ajur.2018.11.005. Epub 2018 Nov 29. Review.

19.

Recent advances in extracellular vesicle research for urological cancers: From technology to application.

Dong L, Zieren RC, Wang Y, de Reijke TM, Xue W, Pienta KJ.

Biochim Biophys Acta Rev Cancer. 2019 Apr;1871(2):342-360. doi: 10.1016/j.bbcan.2019.01.008. Epub 2019 Feb 7. Review.

PMID:
30738098
20.

Computational Modeling of the Crosstalk Between Macrophage Polarization and Tumor Cell Plasticity in the Tumor Microenvironment.

Li X, Jolly MK, George JT, Pienta KJ, Levine H.

Front Oncol. 2019 Jan 23;9:10. doi: 10.3389/fonc.2019.00010. eCollection 2019.

21.

PSMA-targeted [18F]DCFPyL PET/CT-avid lesions in a patient with prostate cancer: Clinical decision-making informed by the PSMA-RADS interpretive framework.

Reyes DK, Demehri S, Werner RA, Pomper MG, Gorin MA, Rowe SP, Pienta KJ.

Urol Case Rep. 2019 Jan 9;23:72-74. doi: 10.1016/j.eucr.2019.01.007. eCollection 2019 Mar.

22.

Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies.

van der Toom EE, Axelrod HD, de la Rosette JJ, de Reijke TM, Pienta KJ, Valkenburg KC.

Nat Rev Urol. 2019 Jan;16(1):7-22. doi: 10.1038/s41585-018-0119-5. Review.

23.

Cooperation among cancer cells: applying game theory to cancer.

Archetti M, Pienta KJ.

Nat Rev Cancer. 2019 Feb;19(2):110-117. doi: 10.1038/s41568-018-0083-7. Review.

PMID:
30470829
24.

Optimization of prostate cancer cell detection using multiplex tyramide signal amplification.

Roy S, Axelrod HD, Valkenburg KC, Amend S, Pienta KJ.

J Cell Biochem. 2019 Apr;120(4):4804-4812. doi: 10.1002/jcb.28016. Epub 2018 Nov 2.

25.

Tumor cell heterogeneity and resistance; report from the 2018 Coffey-Holden Prostate Cancer Academy Meeting.

Miyahira AK, Den RB, Carlo MI, de Leeuw R, Hope TA, Karzai F, McKay RR, Salami SS, Simons JW, Pienta KJ, Soule HR.

Prostate. 2019 Feb;79(3):244-258. doi: 10.1002/pros.23729. Epub 2018 Oct 31. Review.

PMID:
30381857
26.

Publisher Correction: 3D Shape Modeling for Cell Nuclear Morphological Analysis and Classification.

Kalinin AA, Allyn-Feuer A, Ade A, Fon GV, Meixner W, Dilworth D, Husain SS, de Wet JR, Higgins GA, Zheng G, Creekmore A, Wiley JW, Verdone JE, Veltri RW, Pienta KJ, Coffey DS, Athey BD, Dinov ID.

Sci Rep. 2018 Oct 26;8(1):16142. doi: 10.1038/s41598-018-33574-w.

27.

AXL Is a Putative Tumor Suppressor and Dormancy Regulator in Prostate Cancer.

Axelrod HD, Valkenburg KC, Amend SR, Hicks JL, Parsana P, Torga G, DeMarzo AM, Pienta KJ.

Mol Cancer Res. 2019 Feb;17(2):356-369. doi: 10.1158/1541-7786.MCR-18-0718. Epub 2018 Oct 5.

PMID:
30291220
28.

Uptake of Prostate-Specific Membrane Antigen-Targeted 18F-DCFPyL in Cerebral Radionecrosis: Implications for Diagnostic Imaging of High-Grade Gliomas.

Salas Fragomeni RA, Pienta KJ, Pomper MG, Gorin MA, Rowe SP.

Clin Nucl Med. 2018 Nov;43(11):e419-e421. doi: 10.1097/RLU.0000000000002280.

PMID:
30247210
29.

3D Shape Modeling for Cell Nuclear Morphological Analysis and Classification.

Kalinin AA, Allyn-Feuer A, Ade A, Fon GV, Meixner W, Dilworth D, Husain SS, de Wet JR, Higgins GA, Zheng G, Creekmore A, Wiley JW, Verdone JE, Veltri RW, Pienta KJ, Coffey DS, Athey BD, Dinov ID.

Sci Rep. 2018 Sep 12;8(1):13658. doi: 10.1038/s41598-018-31924-2. Erratum in: Sci Rep. 2018 Oct 26;8(1):16142.

30.

Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment.

Moyer CL, Phillips R, Deek MP, Radwan N, Ross AE, Antonarakis ES, Reyes D, Wright J, Terezakis SA, Song DY, DeVille C, Walsh PC, DeWeese TL, Carducci M, Schaeffer EM, Pienta KJ, Eisenberger M, Tran PT.

World J Urol. 2018 Sep 6. doi: 10.1007/s00345-018-2477-2. [Epub ahead of print]

PMID:
30191396
31.

Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on 18F-DCFPyL PET/CT Imaging.

Werner RA, Bundschuh RA, Bundschuh L, Javadi MS, Leal JP, Higuchi T, Pienta KJ, Buck AK, Pomper MG, Gorin MA, Lapa C, Rowe SP.

J Nucl Med. 2018 Dec;59(12):1857-1864. doi: 10.2967/jnumed.118.217588. Epub 2018 Sep 6.

32.

Follow-up of Lesions with Equivocal Radiotracer Uptake on PSMA-Targeted PET in Patients with Prostate Cancer: Predictive Values of the PSMA-RADS-3A and PSMA-RADS-3B Categories.

Yin Y, Werner RA, Higuchi T, Lapa C, Pienta KJ, Pomper MG, Gorin MA, Rowe SP.

J Nucl Med. 2019 Apr;60(4):511-516. doi: 10.2967/jnumed.118.217653. Epub 2018 Sep 6.

PMID:
30190303
33.

O-GlcNAcylation is required for mutant KRAS-induced lung tumorigenesis.

Taparra K, Wang H, Malek R, Lafargue A, Barbhuiya MA, Wang X, Simons BW, Ballew M, Nugent K, Groves J, Williams RD, Shiraishi T, Verdone J, Yildirir G, Henry R, Zhang B, Wong J, Wang KK, Nelkin BD, Pienta KJ, Felsher D, Zachara NE, Tran PT.

J Clin Invest. 2018 Nov 1;128(11):4924-4937. doi: 10.1172/JCI94844. Epub 2018 Sep 24.

34.

Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications.

Werner RA, Bundschuh RA, Bundschuh L, Javadi MS, Higuchi T, Weich A, Sheikhbahaei S, Pienta KJ, Buck AK, Pomper MG, Gorin MA, Lapa C, Rowe SP.

Ann Nucl Med. 2018 Oct;32(8):512-522. doi: 10.1007/s12149-018-1291-7. Epub 2018 Aug 14. Review.

35.

Regarding the Congruence Between 2 Circulating Tumor DNA Sequencing Assays-Reply.

Torga G, Pienta KJ.

JAMA Oncol. 2018 Oct 1;4(10):1431-1432. doi: 10.1001/jamaoncol.2018.2326. No abstract available.

PMID:
30027215
36.

Optimization of Immunofluorescent Detection of Bone Marrow Disseminated Tumor Cells.

Axelrod HD, Pienta KJ, Valkenburg KC.

Biol Proced Online. 2018 Jul 1;20:13. doi: 10.1186/s12575-018-0078-5. eCollection 2018.

37.

Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies.

Sfanos KS, Markowski MC, Peiffer LB, Ernst SE, White JR, Pienta KJ, Antonarakis ES, Ross AE.

Prostate Cancer Prostatic Dis. 2018 Nov;21(4):539-548. doi: 10.1038/s41391-018-0061-x. Epub 2018 Jul 9.

38.

Cancer as a Social Dysfunction-Why Cancer Research Needs New Thinking.

Axelrod R, Pienta KJ.

Mol Cancer Res. 2018 Sep;16(9):1346-1347. doi: 10.1158/1541-7786.MCR-18-0013. Epub 2018 May 21.

39.

Epigenetic control of macrophage polarization: implications for targeting tumor-associated macrophages.

de Groot AE, Pienta KJ.

Oncotarget. 2018 Feb 21;9(29):20908-20927. doi: 10.18632/oncotarget.24556. eCollection 2018 Apr 17. Review.

40.

Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group.

Miyahira AK, Pienta KJ, Morris MJ, Bander NH, Baum RP, Fendler WP, Goeckeler W, Gorin MA, Hennekes H, Pomper MG, Sartor O, Tagawa ST, Williams S, Soule HR.

Prostate. 2018 Aug;78(11):775-789. doi: 10.1002/pros.23642. Epub 2018 May 1. Review.

PMID:
29717499
41.

Ten unanswered questions in cancer: "If this is true, what does it imply"?

Amend SR, de Groot AE, Torga G, Axelrod HD, Reyes DK, Valkenburg KC, Glavaris SA, Pienta KJ.

Am J Clin Exp Urol. 2018 Apr 1;6(2):26-31. eCollection 2018. No abstract available.

42.

Targeting the tumour stroma to improve cancer therapy.

Valkenburg KC, de Groot AE, Pienta KJ.

Nat Rev Clin Oncol. 2018 Jun;15(6):366-381. doi: 10.1038/s41571-018-0007-1. Review.

43.

A Voice From the Past: Rediscovering the Virchow Node With Prostate-specific Membrane Antigen-targeted 18F-DCFPyL Positron Emission Tomography Imaging.

Werner RA, Andree C, Javadi MS, Lapa C, Buck AK, Higuchi T, Pomper MG, Gorin MA, Rowe SP, Pienta KJ.

Urology. 2018 Jul;117:18-21. doi: 10.1016/j.urology.2018.03.030. Epub 2018 Apr 4. No abstract available.

44.

SSTR-RADS Version 1.0 as a Reporting System for SSTR PET Imaging and Selection of Potential PRRT Candidates: A Proposed Standardization Framework.

Werner RA, Solnes LB, Javadi MS, Weich A, Gorin MA, Pienta KJ, Higuchi T, Buck AK, Pomper MG, Rowe SP, Lapa C.

J Nucl Med. 2018 Jul;59(7):1085-1091. doi: 10.2967/jnumed.117.206631. Epub 2018 Mar 23.

45.

Symmetry and symmetry breaking in cancer: a foundational approach to the cancer problem.

Frost JJ, Pienta KJ, Coffey DS.

Oncotarget. 2017 Dec 5;9(14):11429-11440. doi: 10.18632/oncotarget.22939. eCollection 2018 Feb 20.

46.

Diagnosing small bowel carcinoid tumor in a patient with oligometastatic prostate cancer imaged with PSMA-Targeted [18F]DCFPyL PET/CT: Value of the PSMA-RADS-3D Designation.

Shenderov E, Gorin MA, Kim S, Johnson PT, Allaf ME, Partin AW, Pomper MG, Antonarakis ES, Pienta KJ, Rowe SP.

Urol Case Rep. 2017 Dec 19;17:22-25. doi: 10.1016/j.eucr.2017.12.011. eCollection 2018 Mar.

47.

Epithelial and mesenchymal prostate cancer cell population dynamics on a complex drug landscape.

Lin KC, Torga G, Wu A, Rabinowitz JD, Murray WJ, Sturm JC, Pienta KJ, Austin R.

Converg Sci Phys Oncol. 2017 Dec;3(4). pii: 045001. Epub 2017 Aug 30.

48.

PBOV1 as a potential biomarker for more advanced prostate cancer based on protein and digital histomorphometric analysis.

Carleton NM, Zhu G, Gorbounov M, Miller MC, Pienta KJ, Resar LMS, Veltri RW.

Prostate. 2018 May;78(7):547-559. doi: 10.1002/pros.23499. Epub 2018 Mar 9.

49.

Characterization of Urothelial Cancer Circulating Tumor Cells with a Novel Selection-Free Method.

Chalfin HJ, Kates M, van der Toom EE, Glavaris S, Verdone JE, Hahn NM, Pienta KJ, Bivalacqua TJ, Gorin MA.

Urology. 2018 May;115:82-86. doi: 10.1016/j.urology.2018.01.036. Epub 2018 Feb 9.

PMID:
29432873
50.

CXCL12γ Promotes Metastatic Castration-Resistant Prostate Cancer by Inducing Cancer Stem Cell and Neuroendocrine Phenotypes.

Jung Y, Cackowski FC, Yumoto K, Decker AM, Wang J, Kim JK, Lee E, Wang Y, Chung JS, Gursky AM, Krebsbach PH, Pienta KJ, Morgan TM, Taichman RS.

Cancer Res. 2018 Apr 15;78(8):2026-2039. doi: 10.1158/0008-5472.CAN-17-2332. Epub 2018 Feb 5.

Supplemental Content

Loading ...
Support Center